Загрузка...
Alirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials
BACKGROUND: Non‐high‐density lipoprotein cholesterol (non‐HDL‐C) and apolipoprotein (apo) B are better predictors of atherosclerotic cardiovascular disease risk than low‐density lipoprotein cholesterol alone. US and European lipid management guidelines support non‐HDL‐C and apoB as targets for lipid...
Сохранить в:
| Опубликовано в: : | J Am Heart Assoc |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5586424/ https://ncbi.nlm.nih.gov/pubmed/28862926 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.117.005639 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|